Hanna Bonnekoh

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4103526/publications.pdf

Version: 2024-02-01

22 papers 508 citations

759233 12 h-index 22 g-index

26 all docs 26 docs citations

26 times ranked 566 citing authors

#	Article	IF	Citations
1	Treatment of urticarial vasculitis: AÂsystematic review. Journal of Allergy and Clinical Immunology, 2019, 143, 458-466.	2.9	64
2	The global impact of the COVIDâ€19 pandemic on the management and course of chronic urticaria. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 816-830.	5.7	58
3	Translation of cytoplasmic UBA1 contributes to VEXAS syndrome pathogenesis. Blood, 2022, 140, 1496-1506.	1.4	54
4	How to Treat Patients with Chronic Spontaneous Urticaria with Omalizumab: Questions and Answers. Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, 113-124.	3.8	46
5	Skin and Systemic Inflammation in Schnitzler's Syndrome Are Associated With Neutrophil Extracellular Trap Formation. Frontiers in Immunology, 2019, 10, 546.	4.8	39
6	The role of mast cells in autoinflammation. Immunological Reviews, 2018, 282, 265-275.	6.0	34
7	Cold-induced urticarial autoinflammatory syndrome related to factor XII activation. Nature Communications, 2020, 11, 179.	12.8	32
8	Management of urticarial vasculitis: A worldwide physician perspective. World Allergy Organization Journal, 2020, 13, 100107.	3.5	26
9	Long-term efficacy of canakinumab in the treatment of Schnitzler syndrome. Journal of Allergy and Clinical Immunology, 2020, 145, 1681-1686.e5.	2.9	25
10	Use of skin biomarker profiles to distinguish Schnitzler syndrome from chronic spontaneous urticaria: results of a pilot study. British Journal of Dermatology, 2018, 178, 561-562.	1.5	23
11	A novel histopathological scoring system to distinguish urticarial vasculitis from chronic spontaneous urticaria. Clinical and Translational Allergy, 2021, 11, e12031.	3.2	18
12	Topical inflammasome inhibition with disulfiram prevents irritant contact dermatitis. Clinical and Translational Allergy, 2021, 11, e12045.	3.2	14
13	Interâ€rater and intrarater agreement and reliability in clinical staging of hidradenitis suppurativa/acne inversa. British Journal of Dermatology, 2019, 181, 852-854.	1.5	12
14	Characterization of the effects on pruritus by novel treatments for atopic dermatitis. JDDG - Journal of the German Society of Dermatology, 2022, 20, 150-156.	0.8	12
15	Tocilizumab treatment in patients with Schnitzler syndrome: An open-label study. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 2486-2489.e4.	3.8	11
16	Spectrum of Genetic Autoinflammatory Diseases Presenting with Cutaneous Symptoms. Acta Dermato-Venereologica, 2020, 100, adv00091-151.	1.3	9
17	Severe contact dermatitis caused by urushiol in Japanese lacquer. Contact Dermatitis, 2019, 80, 55-56.	1.4	8
18	A distinctive bullous skin reaction associated with enfortumab vedotinâ€ejfv treatment for metastatic urothelial cancer: A case report. JDDG - Journal of the German Society of Dermatology, 2021, 19, 1781-1783.	0.8	6

#	Article	IF	CITATIONS
19	Effective treatment of a lymphocytic variant of hypereosinophilic syndrome with reslizumab. JDDG - Journal of the German Society of Dermatology, 2019, 17, 1171-1172.	0.8	4
20	Treatment of severe heat urticaria with omalizumab – report of a case and review of the literature. Journal of the European Academy of Dermatology and Venereology, 2020, 34, e489-e491.	2.4	3
21	How to Diagnose and Manage Systemic Autoinflammatory Diseases in Childhood. Current Treatment Options in Allergy, 2015, 2, 235-245.	2.2	0
22	Development of tripe palms and soles in a patient with long preâ€existing systemic mastocytosis and newly developed nonâ€small cell lung cancer. Journal of the European Academy of Dermatology and Venereology, 2018, 32, e151-e153.	2.4	0